肝癌免疫组化表型特点
抗体 |
免疫组化 |
阳性率 |
Pan-CK |
+ |
|
AE1AE3 |
-/+ |
约20%(5%-30%) |
35βH11 |
+ |
75%(70-80%) |
CAM5.2 |
+ |
90%-95% |
EMA |
-/+ |
|
CK7 |
罕见 |
15%(0-25%) |
CK20 |
罕见 |
20%(10%-30%) |
Hep Par1 |
+ |
80%-100%(40-100%) |
CK19 |
罕见 |
10%(0-20%) |
CA199 |
- |
|
mCEA |
阴性-罕见 |
5%(0-5%) |
pCEA |
+/- |
70%(60%-95%) |
AFP |
+ |
50%(20%-75%) |
BerEP4 |
罕见 |
25%-33% |
GCDFP-15 |
- |
|
CA125 |
罕见 |
10%(1-20%) |
Vimentin |
罕见 |
5%(0-10%) |
本手册表格中的英文字母及符号解释:
+:Almost always positive;
N或-:almost always negative;
R:rare positive;
S:sometimes positive;
U:uncertain;
NR:not report;
NK:not known;
NA:not applicable;
ND:尚无文献统计资料
CA 125 (Ovariant Cancer Antigen) 卵巢癌抗原
Hep Par 1(Hepatocyte Paraffin 1)
仅供内部参考,欢迎批评指正
版权所有:南京军区南京总医院
技术支持:91360.com